Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
idiopathic pulmonary fibrosis
Biotech
AbbVie buys antibody-focused biotech DJS for $255M
AbbVie is paying $255 million cash to acquire DJS Antibodies and the British biotech's platform for targeting transmembrane proteins.
James Waldron
Oct 20, 2022 12:40pm
AstraZeneca takes home 2 more drug targets from BenevolentAI
Oct 6, 2022 11:06am
Pliant surges as phase 2 data raise hopes for lung disease asset
Jul 11, 2022 9:25am
AstraZeneca collects 2nd lung fibrosis target from BenevolentAI
May 24, 2022 9:05am
AbbVie ditches Morphic's fibrosis program after 'safety signal'
Feb 24, 2022 3:25pm
Endeavor nabs $101M for IPF, cancer trials—and asset shopping
Feb 7, 2022 8:00am
